Omeros (OMER) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

$28.5M

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

$13.2M

Net income growth (year over year)

+152.05%

Net margin

—

Return on equity

—

EPS (trailing twelve months)

$1.92

Book value per share

−$0.71

P/E (trailing twelve months)

11.38

Price to book

—

Debt to assets

117.90%

Payout ratio

—

Dividend yield

—

Company profile

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

• What is OMER's P/E ratio?

  Omeros trades at 11.4 times trailing twelve-month earnings, on an EPS of $1.92.

• How do I buy stock in Omeros (OMER)?

  OMER trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.